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Abstract: Conclusions from previously reported articles have revealed that many commonly used
pharmaceutical excipients, known to be pharmacologically inert, show effects on drug transporters
and/or metabolic enzymes. Thus, the pharmacokinetics (absorption, distribution, metabolism and
elimination) of active pharmaceutical ingredients are possibly altered because of their transport and
metabolism modulation from the incorporated excipients. The aim of this review is to present studies
on the interaction of various commonly-used excipients on pre-systemic metabolism by CYP450
enzymes. Excipients such as surfactants, polymers, fatty acids and solvents are discussed. Based on all
the reported outcomes, the most potent inhibitors were found to be surfactants and the least effective
were organic solvents. However, there are many factors that can influence the inhibition of CYP450,
for instance type of excipient, concentration of excipient, type of CYP450 isoenzyme, incubation
condition, etc. Such evidence will be very useful in dosage form design, so that the right formulation
can be designed to maximize drug bioavailability, especially for poorly bioavailable drugs.
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1. Introduction
The most popular route for drug delivery is oral administration because of pain avoidance, ease
of ingestion, patient compliance and versatility of drug candidates. Moreover, the manufacturing
for oral drug delivery systems is less expensive as the production process is simple and there are no
requirements for sterile conditions [1]. The growth rate of the oral drug delivery market between 2010
and 2017 was 10.3% [2]. Despite all the benefits of oral delivery, poor bioavailability of oral formulations
is a limiting factor that can alter the efficacy and therapeutic effect [3]. Various factors are contributing
to low oral bioavailability including physiological factor, high gastric emptying time, the effect of food,
intestinal barrier and enzymatic degradation of drugs (Table 1). First-pass metabolism is one of the
key factors responsible for poor bioavailability. The extensive metabolism of drugs prior to reaching
the systemic circulation is known as the first-pass metabolism. After oral administration, the drug is
absorbed by the gastrointestinal tract (GIT) and transported to the liver through the portal veins. Then,
the drug is metabolized in the liver before reaching systemic circulation, resulting in a low available
concentration at the intended target site (Figure 1). Due to insufficient plasma concentrations, the
bioavailability of the drug is significantly reduced and therefore a high dose of the drug is required [4].
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Table 1. Examples of drugs with very poor bioavailability with reported reasons.
Drugs PharmacologicalClass
Bioavailability
(%) Reasons References
Alendronate Bisphosphonates 0.59–0.78 Poor solubility andabsorption [5–7]
Atorvastatin Statins 14 P-gp and CYP450 activities [8–10]
Bromocriptine Dopamine receptoragonists 5–10 Extensive first-pass effect [11–13]
Clodronate Bisphosphonates 1 Poor solubility andabsorption [5–7]
Cytarabine Antimetabolites 20 Intestinal and hepaticfirst-pass [14]
Domperidone D2 receptorantagonists 15 Gut and liver first-pass [15]
Doxorubicin Anthracyclineantibiotics 5
Hepatic and intestinal
metabolism [16]
Budesonide Corticosteroids 11 Hepatic first-pass effect [17]
Etidronate Bisphosphonates 5 Poor solubility andabsorption [6,7,13]
Felodipine Calcium channelblockers 15 P-gp and CYP450 activities [17]
Isradipine Calcium channelblockers 15 P-gp and CYP450 activities [18]
Fluvastatin Statins 20 P-gp and CYP450 activities [8–10]
Nimodipine Calcium Channelblockers 13 P-gp and CYP450 activities [19]
Hyoscine Antispasmodics 20 Hepatic metabolism [20]
Ketamine Dissociativeanesthetics 20
Hepatic and intestinal
metabolism [21]
Lovastatin Statins <5 P-gp and CYP450 activities [8–10]
Morphine Opioids 20–33 Gut and liver first-pass [22]
Pyridostigmine Acetylcholinesteraseinhibitors 14 Poor absorption [23]
Naloxone Opioid antagonists 2–10 Extensive first-pass but90% absorption [24]
Naltrexone Opiate antagonists 5–40 First-pass, enterohepaticrecycling [10]
Pamidronate Bisphosphonates 1 Poor solubility andabsorption [5–7]
Pravastatin Statins 17–34 P-gp and CYP450 activities [8–10]
Prochlorperazine Phenothiazines 20 Intestinal and hepaticfirst-pass [25]
Risedronate Bisphosphonates <1 Poor solubility andabsorption [5–7]
Selegiline
Monoamine
oxidase type B
inhibitors
20 Extensive first-pass [26]
Simvastatin Statins 5–48 P-gp and CYP450 activities [8–10]
Sumatriptan Serotonin receptoragonists 20 Hepatic first-pass [27]
Tacrine Cholinesteraseinhibitors 10–30 Hepatic first-pass [28]
Terbutaline Adrenergicreceptor agonists 9–21
Extensive first-pass and
poor absorption [29]
Lidocaine Local anesthetics 3 Hepatic first-pass effect [30]
Tiludronate Bisphosphonates 6 Poor solubility andabsorption [5–7]
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Figure 1. Schematic diagram depicting the route of poor bioavailability after oral administration of
the drugs.
The principle enzymes responsible for first-pass metabolism or biotransformation of drug
molecules are cytochro e P450 (CYP450). CYP450 includes a superfamily of hemeproteins which is
categorized into families and subfamilies based on amino acid sequence ho ology [31]. They are
allotted a family number (for instance, CYP1 or CYP2) followed by a subfamily letter (e.g., CYP1A or
CYP2C) and are distinguished by a number for the individual enzyme or isoforms (e.g., CYP1A2 or
CYP2C19) [31]. According to Coller et al., the most commonly prescribed drugs in the United States
(USA) are reported to be metabolized by CYP1, CYP2 and CYP3 families. The most common enzymes
responsible for oxidation of approximately 79% of these drugs are CYP2C9, CYP2D6, CYP2C19 and
CYP3A4/5 [32].
2. Traditional Strategies to Overcome Pre-Systemic Metabolism
Several novel, as well as traditional, methods are being investigated to circumvent drug metabolism.
Prodrugs, enzyme inhibitors, polymeric excipients, self-emulsifying drug delivery systems (SEDDS)
and liposomes have been investigated over the years as inhibitors to metabolic enzymes.
2.1. Prodrug Approaches
Prodrug is one of the common approaches investigated, according to the literature. Approximately
10% of the drugs in the pharmaceutical market are categorized as prodrugs and one third of small
molecular weight (Mw) drugs are classified as prodrugs [33–38]. Prodrugs are pharmacologically
inert substances which undergo conversion, once inside the body, to release the active ingredient
for its therapeutic effect [39,40]. Prodrugs successfully overcome the drug physicochemical and
biopharmaceutical obstacles, thus enhancing their pharmacokinetic properties such as oral absorption
and metabolism [41,42].
2.2. Enzyme Inhibitors
Another promising strategy to reduce the pre-systemic metabolism is the co-administration of
CYP450 inhibitors with orally administered drugs [43]. Probably, the best-known enzyme inhibitor is
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grapefruit juice, which significantly improves the oral bioavailability of many drugs [44,45]. Food–drug
interaction is a common occurrence and can be significant when the drug’s pharmacokinetics are
altered. The classic example is the interaction between grapefruit juice and felodipine. Felodipine is
known to undergo high pre-systemic metabolism resulting in very low absolute bioavailability with an
average of 15%. A study showed the inhibitory effect of grapefruit juice flavonoids such as quercetin,
naringenin and naringin on CYP3A4, using felodipine as a substrate [45]. The concentration-dependent
inhibition was examined when the flavonoids were co-incubated with felodipine [45]. Moreover, many
studies reported furanocoumarins, present in grapefruit juice, as an inhibitor for CYP450 [46–54].
Bergamottin inhibits CYP1A2, CYP1B1, CYP 2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1,
CYP3A4 and CYP3A5. The dihydroxybergamottin (DHB) and paradisins inhibit CYP1A2, CYP1B1,
CYP2C9, CYP2C19, 2D6 and CYP3A4 [55].
Besides grapefruit juice, many drugs in the market such as ketoconazole, Troleandomycin,
saquinavir, diltiazem and fluconazole exhibit an enzyme inhibitory effect resulting in improved
bioavailability of many drugs [43,56]. For instance, the oral bioavailability of alfentanil was increased
19-fold with troleandomycin [57]. However, co-administration of enzyme inhibitors can lead to
adverse drug effects which also includes fatal events. For example, when clarithromycin (inhibitor) is
co-administered with astemizole, terfenadine or cisapride (substrates), a severe ventricular arrhythmia
may occur [58].
3. Other Approaches
These include polymeric excipients, self-emulsifying drug delivery systems (SEDDS) and
liposomes. Normally, polymers are used as enteric coatings for different types of drugs to overcome
hydrolytic instability [59]. Some polymers, such as polycarbophil and carbomer, demonstrate
inhibitory effects on trypsin, which decrease pre-systemic metabolism in the intestine. That means
drugs incorporated in such polymers can be protected from pre-systemic degradation by trypsin [60].
Similarly, most of the studies on SEDDS and liposomes focus on increased solubility by these systems
and their protective property towards pre-systemic metabolism is hardly examined [43].
3.1. Novel Approach to Overcome Pre-Systemic Metabolism
The addition of commonly-used pharmaceutical excipients can be a potential solution to these
problems. Pharmaceutical excipients are ingredients other than the active pharmaceutical ingredient
(API) present in a finished pharmaceutical drug formulation. These are frequently used as lubricants,
diluent, binders, flavorings, coating and coloring agents for the formulation. These substances are
often therapeutically inert [61].
The functional roles of pharmaceutical excipients include modulating bioavailability and solubility
of APIs, increasing the stability of APIs in the dosage form, maintaining the osmolarity and/or pH of the
liquid formulations, preventing dissociation and aggregation, etc. Recently, addition of pharmaceutical
excipients in drug formulations have gained attention which can alter the pharmacokinetics of drugs,
resulting in improved bioavailability [61]. The aim of this review article is to survey the current
literature and evaluate the effect of different pharmaceutical excipients on metabolic enzymes. This
review looks at the effect on surfactant, polymers, etc. excipients on the expression of cytochrome
P450 enzymes.
3.2. Effect of Excipients
Substances that can enhance or inhibit cytochrome P450 activity can alter the rate of drug
metabolism, leading to an increase or decrease in drug bioavailability. There are many studies on new
materials as drug delivery vehicles, including vesicles, block copolymer micelles, degradable polymer
particles, dendrimers, polymer prodrugs and lipid nanoparticles; however, the effect of excipients used
is often ignored. For instance, liquid acetaminophen, which contains propylene glycol, is less toxic
than solid preparations with no propylene glycol. The main reason for acute hepatic failure in Europe
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and the United States is acetaminophen [62,63]. Its toxicity is due to the reductive metabolism via
CYP2E1 [64]. Liquid formulation of acetaminophen contains a solubilizing agent called propylene
glycol, which is used to dissolve the drug in aqueous solution [65]. Since children ingest liquid
formulation and are less vulnerable to its toxicity, a single-blinded cross-over study was conducted to
compare metabolism of solid and liquid acetaminophen 15 mg/kg dose by CYP2E1, using 15 healthy
adults as volunteers. As a result, the measured AUCs for the metabolites were 16% lower than solid
formulation. This is because propylene glycol is a competitive antagonist to CYP2E1; hence, it shows
the protective effect in liquid formulation [65].
One method by which excipients may alter the drug metabolism is by inhibiting CYP450 enzymes
present in cellular microsomes [61].
3.3. Surfactants
Surfactants, also known as surface-active agents, possess hydrophilic (polar) and hydrophobic
(non-polar) characteristics. The hydrophobic (non-polar) part is referred to as the tail group and the
hydrophilic (polar) part as the head group. Surfactants are normally used to increase the solubility of
the drugs and to decrease the interfacial tension between the drug and the medium [66]. Surfactants
can be categorized into four different groups: anionic, cationic, zwitterionic and non-ionic surfactants
(Table 2). Anionic surfactants carry a negative charge, whereas cationic surfactants carry a positive
charge on their hydrophilic head. Zwitterionic surfactants have the potential to carry both positive
and negative charges [66].
Cremophor EL is a heterogeneous non-ionic surfactant made up of castor oil and ethylene oxide
with a molar ratio of 1:35 [67]. Cremophor EL helps in solubilizing many hydrophobic drugs which
include photosensitizers, immunosuppressive agents, sedatives, anesthetics and anticancer drugs
(experimental) [67]. Different in vitro studies have been reported for the impact of Cremophor EL on
the metabolism of drugs [68–70]. In 2010, a study focused on the effect of Cremophor EL on CYP3A4
and CYP2C9 mediated metabolism of testosterone and diclofenac, respectively [68]. Cremophor EL was
tested at different concentrations (0.01–100 mM) using human liver microsomes in vitro. As a result,
the inhibitory effect of Cremophor EL was found to be concentration dependent. The half-maximal
inhibitory concentration (IC50) of the CYP3A4- and CYP2C9-mediated metabolism were determined as
0.60 and 0.03 mM, respectively.
Mudra et al. further showed that solubilizing agents inhibited verapamil-N-demethylase
activity in vitro and in situ. The rate of verapamil-N-demethylation was reduced in the presence of
Cremophor EL, suggesting moderate inhibition of CYP3A4: 20.7% and 21.8%, in situ and in vitro
at 47.5 µg/mL, respectively [69]. The inhibition of CYP450 by polyethoxylated solubilizing agents
(e.g., Cremophor EL, Tween 80) can be attributed to the collective evidence that supports the following
hypothesis: The drug absorption is altered in the presence of polyethoxylated solubilizing agents
due to agent-produced membrane fluidization, causing in local environment perturbation required
for protein to function [70–73]. Similarly, the outcomes in this article are reliable with agent-induced
fluidization of microsomal membrane resulting in perturbation of the enzyme micro-environment,
thus decreasing CYP3A4 function.
To support this hypothesis, another study on Cremophor EL presented results consistent with the
previous studies. In vitro metabolism of 7-ethoxycoumarin was studied at three different concentration
of the surfactant (0.03%, 0.06% and 0.1% w/v). Various enzymes are responsible for metabolism of
ethoxycoumarin, but the major enzymes are CYP450 1A2, CYP450 1A1 and CYP450 2B. Increasing the
concentration of Cremophor EL decreased the metabolic activity of these enzymes [68,74]. The CYP450
activities were reduced from 97% to 93% when surfactant concentration was increased from 0.03% to
0.10%. This is because the surfactant concentration above its critical micellar concentration (CMC)
value disrupts the CYP450 enzymes membrane, causing an inhibitory effect. In contrast, below its
CMC value, there is less disruption [74].
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In 2004, Gonzalez et al. investigated the effect surfactants have on the metabolism of the CYP3A2
substrate by Midazolam (MDZ) by determining the intrinsic clearance (Clint) of MDZ in rat hepatocyte
and rat microsome systems [75]. In the rat hepatocytic system, the Clint of MDZ decreased significantly
above its critical micellar concentration (CMC) at 0.03% (Clint/0.03% = 70.3% ± 2.1%) and 0.3%
(Clint/0.3% = 54.9% ± 2.2%), whereas the Clint of MDZ was not altered significantly below its CMC
(at 0.0003% and 0.003%). Similar outcomes were observed with rat liver microsomes; significant
decrease in Clint of MDZ at 0.03% (Clint/0.03% = 89.5 ±3.7 µL/min/mg protein) and 0.3% (Clint/0.3% =
35.0 ±0.8 µL/min/mg protein) of the Cremophor EL. Thus, the addition of Cremophor EL reduced the
intrinsic clearance of MDZ by inhibiting CYP450 in both systems [75].
Taxol is an active ingredient used for refractory ovarian cancer, lung cancer and breast cancer. It
is readily metabolized by the CYP450 system in the liver. A study conducted by Carlos et al. (1994)
illustrated that Cremophor EL had the most significant effect on taxol metabolism, by the CYP450
system, compared to other co-administered drugs (diphenhydramine, cimetidine and dexamethasone).
In human and rat liver microsomes, the formation of 6α-hydroxytaxol was completely prevented
by Cremophor EL at 20 µL/mL. In human liver slices, Cremophor EL reduced the formation of
6α-hydroxytaxol as well as the ratio of metabolite to parent drug at 20 µL/mL [76]. However, at
2 µL/mL, Cremophor EL showed very little effect. These results suggest that Cremophor EL indirectly
reduces the taxol uptake by the liver. To conclude from all the studies, the inhibition of CYP450 enzymes
by Cremophor EL seems to be dependent on the concentration of surfactant, type of isoenzyme and
type of microsomal assay.
Cremophor RH-40 is found in many oral drug formulations, which is mainly used to improve
solubilization of the drugs, such as Tegretol, Anafranil and Sandimmun Neoral. Cremophor RH-40 has
a different molar content of ethylene oxide (45 mol) than Cremophor EL [77]. The inhibition of CYP450
enzymes by Cremophor RH-40 has been reported in many studies [63]. Christiansen et al. examined
the effect of non-ionic surfactants on CYP3A4 and CYP2C9 enzymes [68]. The inhibitory action of
Cremophor RH40 (IC50 = 0.80 mM) was found to be less than Cremophor EL (IC50 = 0.60 mM) for
CYP3A4, whereas stronger inhibition was reported with a similar IC50 value (0.03 mM) for CYP2C9.
To understand the action of Cremophor RH40 in biotransformation, it was examined for its inhibitory
effect on CYP3A4 in vitro as well as in vivo [61]. According to the in vitro study conducted by Ren et al.
(2008), the inhibition rate of CYP3A4 by Cremophor RH40 was 99.40%. Furthermore, single and
multiple doses of Cremophor RH40 were examined in male Sprague-Dawley rats for its impact on
MDZ metabolism. In comparison to control saline, Cremophor RH40 increased the area under curve
(AUC0-∞) of MDZ up to 1.1-fold and decreased the production of 1′-Hydroxymidazolam (1′-OH-MDZ)
up to 0.44-fold in a single dose. The MDZ AUC0-∞ was increased by 1.69-fold and 1’-OH-MDZ AUC0-∞
was decreased by 0.9-fold in a multiple-dose regimen [61].
These results are consistent with the recent study on a Cremophor RH40-based self-micro
emulsifying drug delivery system (SMEDDS) [78]. A significant decrease in 1′-OH-MDZ production
was observed (p < 0.05), when the concentration of Cremophor RH40 was increased from 0.05% to
3% w/v. Studies have revealed that chemotherapeutic substances can downregulate the CYP3A gene
expression [79,80]. Therefore, Western blot analysis was performed to examine the effect of SMEDDS
on the CYP3A activity. As a result, Cremophor RH40-based SMEDDS reduced the CYP3A protein
expression levels at dilutions ranging from 1:50 to 1:100. Another study reported a similar significant
inhibition of CYP3A4 and CYP2C19 enzymes in vitro by Cremophor RH40 when rabeprazole was used
as a probe drug (p < 0.05) [81]. It was concluded that these inhibitory effects involved direct action or
micelle formation to disrupt CYP activities.
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Table 2. Summary of the effect of surfactants on CYP activities.
Surfactants Substrates Mechanism of Action Structures Type References
Brij 35 7-ethoxycoumarin
Increased CYP3A4
inhibition with
increased surfactant
concentration
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3.4. Polymers 
Polymers are macromolecular compounds and constitute a large and diverse group of 
substances, including synthetic polymers, semi-synthetic polymers, natural polymers and 
fermentation products (Table 3). These polymers are commonly used as excipients in pharmaceutical 
dosage forms; parenterally, orally, nasally, rectally, intravaginally, inhalationally and topically, on 
the oral mucosa and in ophthalmic preparations [84]. 
Lihui Qiu et al. evaluated the in vitro inhibition of six CYP isoforms by different mPEGx-PCLx 
(methoxy poly(ethylene glycol)-poly(ε-caprolactone)) amphiphilic copolymer micelles: mPEG2k-
PCL2k, mPEG2k-PCL3.5k, mPEG2k-PCL5k and mPEG2k-PCL10k. The inhibitory effect was found 
to be concentration-dependent in manner [85]. All CYP450 enzymes were significantly inhibited by 
mPEG2k-PCLx when the concentration was increased to 1000 μg/mL. For example, the CYP activities 
were reduced to 68.7% for CYP2D2, 64.6% for CYP2C6, 40.4% and 33.5% for CYP3A2/1, 38.1% for 2B1, 
26.2% for 2C11 and 9.4% for 1A2 by mPEG2k-PCL2k at 1000 μg/mL. The extent of inhibition, ranked 
downwards, was as follows: mPEG2k-PCL2k > mPEG2k-PCL3.5k > mPEG2k-PCL5k > and mPEG2k-
PCL10k [85].  
Similarly, Martin and co-workers investigated the effect of 10 commonly-used polymers on 
seven CYP isoforms (2E1, 3A4, 3A5, 2C9, 2C19, 1A2 and 2D6). As shown in Table 4, nine out of ten 
polymers inhibited CYP activities. Cytochromes 2E1, 3A5, 2C9, 2C19 and 2D6 were inhibited by 
polyethylene glycol (PEG), while 2E1, 3A4, 3A5 and 2C9 were downregulated by pluronic F68. 
Pluronic F127, polyvinyl acetate (PVA) and sodium carboxymethyl cellulose (NaCMC) inhibited 2E1, 
2E1 and 1A2, respectively. Hydroxypropyl methylcellulose (HPMC) inhibited 2E1 and 3A5, whereas 
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Table 2. Cont.
Surfactants Substrates Mechanism of Action Structures Type References
Sucrose laurate TestosteroneDiclofenac
Increased CYP3A4 and
CYP2C9 inhibition in
concentration-dependent
manner
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Polymers are macromolecular compounds and constitute a large and diverse group of 
substances, including synthetic polymers, semi-synthetic polymers, natural polymers and 
fermentation products (Table 3). These polymers are commonly used as excipients in pharmaceutical 
dosage forms; parenterally, orally, nasally, rectally, intravaginally, inhalationally and topically, on 
the oral mucosa and in ophthalmic preparations [84]. 
Lihui Qiu et al. evaluated the in vitro inhibition of six CYP isoforms by different mPEGx-PCLx 
(methoxy poly(ethylene glycol)-poly(ε-caprolactone)) amphiphilic copolymer micelles: mPEG2k-
PCL2k, mPEG2k-PCL3.5k, mPEG2k-PCL5k and mPEG2k-PCL10k. The inhibitory effect was found 
to be concentration-dependent in manner [85]. All CYP450 enzymes were significantly inhibited by 
mPEG2k-PCLx when the concentration was increased to 1000 μg/mL. For example, the CYP activities 
were reduced to 68.7% for CYP2D2, 64.6% for CYP2C6, 40.4% and 33.5% for CYP3A2/1, 38.1% for 2B1, 
26.2% for 2C11 and 9.4% for 1A2 by mPEG2k-PCL2k at 1000 μg/mL. The extent of inhibition, ranked 
downwards, was as follows: mPEG2k-PCL2k > mPEG2k-PCL3.5k > mPEG2k-PCL5k > and mPEG2k-
PCL10k [85].  
Similarly, Martin and co-workers investigated the effect of 10 commonly-used polymers on 
seven CYP isoforms (2E1, 3A4, 3A5, 2C9, 2C19, 1A2 and 2D6). As shown in Table 4, nine out of ten 
polymers inhibited CYP activities. Cytochromes 2E1, 3A5, 2C9, 2C19 and 2D6 were inhibited by 
polyethylene glycol (PEG), while 2E1, 3A4, 3A5 and 2C9 were downregulated by pluronic F68. 
Pluronic F127, polyvinyl acetate (PVA) and sodium carboxymethyl cellulose (NaCMC) inhibited 2E1, 
2E1 and 1A2, respectively. Hydroxypropyl methylcellulose (HPMC) inhibited 2E1 and 3A5, whereas 
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3.4. Polymers 
Polymers are macromolecular compounds and constitute a large and diverse group of 
substances, including synthetic polymers, semi-synthetic polymers, natural polymers and 
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PCL2k, mPEG2k-PCL3.5k, mPEG2k-PCL5k and mPEG2k-PCL10k. The inhibitory effect was found 
to be concentration-dependent in manner [85]. All CYP450 enzymes were significantly inhibited by 
mPEG2k-PCLx when the concentration was increased to 1000 μg/mL. For example, the CYP activities 
were reduced to 68.7% for CYP2D2, 64.6% for CYP2C6, 40.4% and 33.5% for CYP3A2/1, 38.1% for 2B1, 
26.2% for 2C11 and 9.4% for 1A2 by mPEG2k-PCL2k at 1000 μg/mL. The extent of inhibition, ranked 
downwards, was as follows: mPEG2k-PCL2k > mPEG2k-PCL3.5k > mPEG2k-PCL5k > and mPEG2k-
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Similarly, Martin and co-workers investigated the effect of 10 commonly-used polymers on 
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Recently, Tween 80 has been reported to inhibit different isoenzymes of CYP450: 3A4, 2C9, 1A1,
1A2 and 2B. Tween 80 (polysorbate 80) is the most commonly-used hydrophilic non-ionic surfactant
with the ability to i prove the solubility of com unds [69]. Tween 80 is d rived from oleic ac d and
polyethoxylated orbitol and has been used in reclinical and clinical drug formulations [69]. Moderate
inhibition of CYP3A4 and CYP2C9 by Tween 80 was determined. The IC50 value for CYP3A4 and
CYP2C9 was found to be 0.40 and 0.04 mM, respectively. Christiansen et al. and Rao et al. illustrated the
inhibition of CYP450 to be a concentration-dependent manner. For example, w en the concentration of
Tween 80 in SMEDDS was increas d from 0.05% to 3% (w/v), the 1′-OH-MDZ production was reduced
from ~80% to 30%. The in vitro metabolism of 7-ethoxycoumarin was reduced from 85% to 65% when
the concentration of Tween 80 was increased from 0.03% to 0.10% [68].
The incubati n of Tween 80 with rat hepatocytes reduced lint of MDZ significa tly, above its
CMC (Clint/0.03% = 75. % ±1.6%; Clint/0.3% 79.2% ±1.5%, p < 0.05), w ereas the inhibitory ffect
of Tween 80 was reported below its CMC with rat liver microsomes (Clint/0.003% = 70% ± 5.7%,
Clint/0.03% = 66.9% ± 1.0%, Clint/0.3% = 8.24% ± 0.28%, p < 0.05) [78]. A similar study reported the
inhibition of CYP3A4 b approximately 20% with a Tween 80 concentratio of 50 mM [61]. Mudra et
al. measured the impact of Tween 80 on intestinal verapamil-N-demethylation activity in-situ and
in vitro. The inhibition rate was found to be 56.3% (in-situ) and 13.5% (in vitro) at 25 µg/mL, reflecting
the reduction of CYP3A activity [69].
Tween 20 (Polysorbate 20) and Tween 80 are composed of the same hydrophilic group but different
hydrophobic groups. Tween 20 has a mixture of palmitic, stearic, lauric and myristic acids, whereas
Tween 80 contains oleic, linoleic and stearic acids [61]. According to Ren et al. and Randall et al.,
Tween 20 is a more potent inhibitor than Tween 80. The production of 1′-OH-MDZ was inhibited by
around 80% at 50 mM Tween 20 concentration. It also decreased the metabolism of 7-ethoxycoumarin
from 66% to 56% at a concentration ranging from 0.03% to 0.10% v/v [61,74].
Triton X-100 (TX-100) is an octylphenol polyethoxylated non-ionic surfactant. Its structure
consist of poly(ethylene glycol) with a 4-(1,1,3,3-tetramethylbutyl)phenyl group [82]. TX-100 has been
reported as a strong inhibitor for CYP450 enzymes. It reduced the metabolism of CYP3A4 substrates:
7-ethoxycoumarin by 54% and midazolam by 99.8% [74,81]. The interaction of TX-100 with CYP450
in Prochilodus scrofa was studied using antioxidant and mono-oxygenase system. The CYP content
at 0.05 mM of TX-100 was found to be 0%, explaining the stronger inhibition of CYP450. Similarly,
competitive inhibition of CYP1A1 by TX-100 was reported far below its CMC value (250 µM) [83].
Furthermore, multiple studies pointed out the ability of other surfactants to interfere with CYP450,
which can lead to improved bioavailability of drugs. The surfactants that were reported to show
inhibitory actions are listed in Table 2.
Int. J. Mol. Sci. 2020, 21, 8224 9 of 21
3.4. Polymers
Polymers are macromolecular compounds and constitute a large and diverse group of substances,
including synthetic polymers, semi-synthetic polymers, natural polymers and fermentation products
(Table 3). These polymers are commonly used as excipients in pharmaceutical dosage forms; parenterally,
orally, nasally, rectally, intravaginally, inhalationally and topically, on the oral mucosa and in ophthalmic
preparations [84].
Table 3. Different types of polymers with some examples.
Polymers Examples
Natural
Sodium alginate
Gelatin
Chitosan
Semi-synthetic Cellulose derivatives
Synthetic
Polyethylene glycols
Poloxamers
Polyactides
Polyamides
Acrylic acid polymers
Fermentation products Xanthan gum
Lihui Qiu et al. evaluated the in vitro inhibition of six CYP isoforms by different mPEGx-PCLx
(methoxy poly(ethylene glycol)-poly(ε-caprolactone)) amphiphilic copolymer micelles: mPEG2k-PCL2k,
mPEG2k-PCL3.5k, mPEG2k-PCL5k and mPEG2k-PCL10k. The inhibitory effect was found to be
concentration-dependent in manner [85]. All CYP450 enzymes were significantly inhibited by
mPEG2k-PCLx when the concentration was increased to 1000 µg/mL. For example, the CYP activities
were reduced to 68.7% for CYP2D2, 64.6% for CYP2C6, 40.4% and 33.5% for CYP3A2/1, 38.1% for
2B1, 26.2% for 2C11 and 9.4% for 1A2 by mPEG2k-PCL2k at 1000 µg/mL. The extent of inhibition,
ranked downwards, was as follows: mPEG2k-PCL2k > mPEG2k-PCL3.5k > mPEG2k-PCL5k > and
mPEG2k-PCL10k [85].
Similarly, Martin and co-workers investigated the effect of 10 commonly-used polymers on seven
CYP isoforms (2E1, 3A4, 3A5, 2C9, 2C19, 1A2 and 2D6). As shown in Table 4, nine out of ten polymers
inhibited CYP activities. Cytochromes 2E1, 3A5, 2C9, 2C19 and 2D6 were inhibited by polyethylene
glycol (PEG), while 2E1, 3A4, 3A5 and 2C9 were downregulated by pluronic F68. Pluronic F127,
polyvinyl acetate (PVA) and sodium carboxymethyl cellulose (NaCMC) inhibited 2E1, 2E1 and 1A2,
respectively. Hydroxypropyl methylcellulose (HPMC) inhibited 2E1 and 3A5, whereas polyvinyl
pyrrolidone (PVP) downregulated 3A4 and 1A2. Other polymers, such as Kollicoat, in this study also
inhibited specific enzymes, apart from hydroxypropyl cellulose (HPC), which exhibited no effect on
any of the enzymes [86].
Huang et al. used the Hill equation and Lineweaver–Burk plots to determine the inhibitory effect
of pluronic F68 (F68) on CYP3A4. The dose-dependent inhibition was reported with the Ki and IC50
values for F68 averaged 0.16 and 0.11 mg/mL, respectively [87]. The mechanism of action was based
on the previously reported inhibitory effect study, which includes the direct interaction with CYP450
enzymes, cell membrane disruption and alteration of cell membrane [75].
Another study tested 22 commonly used excipients, which included sodium alginate, PEG4000,
PEG1000, PEG6000 and PEG 2000. All the listed polymers inhibited 1′-OH-MDZ formation in
the following order (from strong to weak): Sodium alginate > PEG4000 > PEG1000 > PEG6000 >
PEG2000 [61]. The physical and chemical nature of each excipient clearly play a major role in their
inhibitory capacity. Thus, sodium alginate was the most effective inhibitor compared to the other
polymers due to its ability to disrupt CYP3A4 activity strongly. On the other hand, the outcomes of
this study were limited to CYP3A4. As previously mentioned, there are many families and subfamilies
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of CYP450. There is a possibility that the least effective polymer (PEG2000) could be the most effective
on other CYP450 isoenzymes.
Table 4. Effect of different polymers on activities of CYP 2E1, 3A5, 2C9, 2C19, 1A2 and 2D6.
Polymer
IC50 Values (µM)
CYP2E1 CYP3A4 CYP3A5 CYP2C9 CYP2C19 CYP1A2 CYP2D6
PEG 75.3 ± 2.1 - 78.0 ± 17.8 365.6 ± 32.8 139.0 ± 22.4 - 409.6 ± 34.5
F68 203.7 ± 48.3 59.1 ± 13.6 209.9 ± 29.7 244.8 ± 13.2 - - -
F127 218.9 ± 13.3 - - - - - -
NaCMC - - - - - 224.7 ± 14.8
HPC - - - - - - -
HPMC 253.5 ± 17.9 - 19.4 ± 0.6 - - - -
PVA 548.9 ± 30.4 - - - - - -
Kollicoat 598.1 ± 26.1 - - - - 10.0 ± 3.9 89.9 ± 2.9
HG 141.2 ± 14.1 - - - - 40.9 ± 8.4 -
PVP - 107.3 ± 11.2 - - - 78.3 ± 4.2 -
Pluronic P85 (P85) is a block copolymer consisting of two equal polyoxyethylene chains joined by
a polyoxypropylene chain. A study revealed that P85 strongly inhibited norverapamil formation by
CYP3A in a concentration-dependent manner [88]. The study included enterocyte-based metabolism,
where the P85 concentrations used were 0.01% and 0.1% v/v. Compared to other polymers in the
study, P85 reduced the formation of norverapamil by around 25% and 50% at 0.01% and 0.1% v/v,
respectively [88].
3.5. Fatty Acids
Fatty acids (FA) are the main components of phospholipids, triacylglycerols and many complex
lipids. FAs are present in the majority of dietary fat in humans. Different foods provide a variety of
fatty acids. In addition, the human body can synthesize them, either from other fatty acids or nonlipid
precursors, e.g., glucose. In recent years, studies have revealed that various FAs have a wide range of
microbicidal activity against several Gram-positive and Gram-negative bacteria, as well as enveloped
viruses, including S. aureus and N. gonorrhoeae [89,90]. For instance, lauric acid (LA) was found to be
the most potent inhibitor for the growth of Gram-positive bacteria. These direct or indirect inhibitory
effects are due to the destabilization of the bacterial cell membrane caused by fatty acids [91–95].
Besides their potent microbicidal activity, FAs can also reduce pre-systemic metabolism of drugs
by inhibiting CYP450 enzymes. The effect of saturated and unsaturated fatty acids on CYP3A4, 2E1,
2D6, 2C19, 2C9, 2C8, 2B6, 2A6 and 1A2 were studied using midazolam 1-hydroxylation, chlorzoxazone
6-hydroxylation, dextromethorphan O-demethylation, mephenytoin 4-hydroxylation, diclofenac
4-hydroxylation, amodiaquine N-deethylation, bupropion hydroxylation, coumarin 7-hydroxylation
and phenacetin O-deethylation, respectively. As a result, out of all the saturated fatty acids, lauric acid
showed potential inhibition of 2B6. Myristic acid inhibited 1A2 (IC50 = 15.8 µM), 2B6 (IC50 = 10.7 µM),
2C8 (IC50 = 13.3 µM) and 2C9 (IC50 = 36.1 µM). One of the mono-unsaturated fatty acids, oleic acid,
inhibited all the CYP isoforms except for CYP2E1, CYP2C19 and CYP2A6. Similarly, arachidonic
acid inhibited activities of CYP3A4, CYP2C19, CYP2C9, CYP2C8, CYP2B6 and CYP1A2. Other FAs
also showed a distinct inhibitory effect on different isoforms: gondoic acid inhibited all except 2C8;
linoleic acid inhibited CYP2B6, CYP2C8 and CYP2C9; linolenic acid inhibited CYP1A2, CYP2B6,
CYP2C8 and 2C9; and timnodonic acid inhibited 2C8 (Table 5) [96]. Amongst all the isoenzymes, the
majority of FAs inhibited CYP2C8 activity. This can be attributed to the large active site on CYP2C8,
which allows different sized substrates to accommodate. It also has a peripheral FA binding site
that can alter the dynamics of the main active site, affecting the reaction catalyzed by this enzyme.
Moreover, it is responsible for the transformation of polyunsaturated FAs to epoxide products (signaling
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agents). Hence, the unsaturated fatty acids are potent inhibitors for CYP enzymes than saturated fatty
acids [97,98].
Table 5. Effect of fatty acids on nine CYPs: 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2E1 and 3A4.
Fatty Acid
Absolute IC50 (µM)
1A2 2A6 2B6 2C8 2C9 2C19 2D6 2E1 3A4
Arachidonic acid 9.7 21.4 4.6 1.3 3.3 23.2 18.3 61.7 11.7
Behenic acid >30 >30 >30 >30 >30 >30 >30 >30 >30
Cervonic acid 6.3 11.7 6.7 1.2 2.6 15.8 5.6 44.4 7.5
Gondoic acid 16.2 81.9 16.6 6.0 17 >100 >100 >100 >100
Lauric acid >100 >100 21.5 42.9 >100 >100 >100 >100 >100
Linoleic acid 13.3 28.9 7.1 1.0 7.4 55.8 17.5 58.9 18.5
α-Linolenic acid 8.8 13.5 9.7 4.4 10.6 53.3 34.3 67.2 36.9
Myristic acid 15.8 >100 10.7 13.3 36.1 >100 >100 >100 >100
Nervonic acid >11.1 >11.1 >11.1 >11.1 >11.1 >11.1 >11.1 >11.1 >11.1
Oleic acid 11.2 25 8.2 4.4 5.7 98.9 18.1 83.8 11.4
Palmitic acid >100 >100 90.5 >100 >100 >100 >100 >100 >100
Palmitoleic acid 7.8 36.2 8 9.7 11.9 58.1 30.3 72.1 26.5
Stearic acid >33.3 >33.3 >33.3 >33.3 >33.3 >33.3 >33.3 >33.3 >33.3
Timnodonic acid 8.2 17.4 5.9 1.5 3.8 13.8 5.7 77.4 16
The results are consistent with a published study on inhibitory effect of saturated and
polyunsaturated fatty acids by Yao and co-workers. Two saturated (palmitic acid and stearic acid)
and five polyunsaturated fatty acids (linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic
acid and docosahexaenoic acid) were examined for their effect on six isoforms of CYPs (1A2, 3A4, 2C9,
2C19, 2E1 and 2D6). As shown in Table 6, saturated fatty acids showed no inhibitory effect, while
all polyunsaturated fatty acids inhibited all six isoforms [99]. These polyunsaturated fatty acids had
little inhibitory effect at low concentrations, whereas there was a complete inhibition of all isoforms at
200 µM. One potential explanation based on the results is that, at high concentration, polyunsaturated
fatty acids disrupt the microsomal membrane, which prevents the binding of the drug to the active
site of the CYP450 enzyme [99]. However, other studies have reported that the CYP enzymes can
also catalyze the metabolism of polyunsaturated fatty acids. Thus, fatty acids can act as a common
substrate for the active site and compete with drugs to bind with CYP enzymes [100,101]. Therefore,
the mechanism of inhibition remains unknown.
Table 6. Effect of saturated and unsaturated fatty acids where, saturated fatty acids showed NI (no
inhibition) and unsaturated inhibited all CYP isoforms.
Fatty Acids IC50
CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP2E1 CYP3A4
Palmitic acid NI NI NI NI NI NI
Stearic acid NI NI NI NI NI NI
Linoleic acid 74 4.1 15 192 113 49
Linolenic acid 52 8.1 9.3 151 82 61
Arachidonic acid 37 3.5 4.8 113 67 48
Eicosapentaenoic acid 41 4.4 4.4 127 53 54
Docosahexaenoic acid 41 2.9 6.7 122 65 34
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4. Co-Solvents/Solvents
In the last few decades, the effect of organic solvents (such as acetonitrile) on CYP-mediated
metabolism has been reported by many researchers [102–109]. Most of the in vitro studies include
organic solvents to dissolve the compounds and prepare the samples for analysis [110–114]. However,
at higher concentrations, these organic solvents inhibit different isoforms of CYPs. Li et al. evaluated
the inhibitory effect of five organic solvents (dimethyl sulfoxide (DMSO), acetonitrile, methanol, ethanol
and acetone) on five CYP isoforms [115]. All organic solvents at 10% v/v inhibited CYPs activities,
whereas >10% inhibition of CYP2D and >40% inhibition of CYP2E (except acetonitrile) was reported at
1% v/v. Overall, the organic solvents showed concentration-dependent inhibition. The inhibitory effect
of organic solvents is summarized in Figure 2. DMSO and ethanol showed highest inhibitory effect
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Figure 2. Illustrates the inhibition of CYP2C, CYP2D, CYP2E, CYP3A and CYP1A by acetonitrile,
methanol, ethanol, acetone and DMSO at 1% and 10% concentrations.
Another study demonstrated similar results with DMSO. When diazepam was dissolved in DMSO,
the rCYP3A4 activity was inhibited in a mixed-type or competitive manner [116]. The inhibition of
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rCYP3A4 was concluded to be concentration- and time-dependent. The DMSO inhibitory constant (Ki)
value for the formation of temazepam and nordiazepam was found to be 24 and 6 mM, respectively.
In 2009, the effect of co-solvent on diclofenac and S-warfarin metabolism by CYP2C9 was studied
using ethanol [117]. The inhibitory effect was determined to be substrate dependent. The inhibition
of S-warfarin metabolism required less ethanol concentration compared to diclofenac metabolism.
Ethanol could inhibit S-warfarin metabolism at a low concentration of 17 mM (0.1% v/v), whereas
it required 510 mM (3.0% v/v) of ethanol to competitively inhibit CYP2C9. Ethanol also presented
concentration-dependent inhibition for both substrates: S-warfarin and diclofenac.
Eight organic solvents have been studied for their effects on CYP3A4 activity using pooled human
microsomes [102]. The hydrophilic organic solvents used for this study were DMSO, acetonitrile,
methanol, 1-propanol, ethanol, polyethylene glycol, propylene glycol and N,N-dimethylformamide.
All organic solvents, except methanol, had significantly decreased testosterone 6β-hydroxylation
activity, which reflected the inhibition of CYP3A4. In contrast, only DMSO and polyethylene glycol
showed potential inhibitory effect on midazolam 1′-hydroxylation activity. Similar to this study, DMSO
showed strongest inhibition for both metabolic activities. Moreover, the inhibition of testosterone
6β-hydroxylation activity by DMSO was in a concentration-dependent manner: from 10% to 50%
inhibition at from 0.1% to 1% v/v concentration. The summary of all the reported organic solvents is
shown in Figure 3.
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Class 3 drugs (high aqueous solubility and low intestinal permeability). Gene expression of the main
metabolizing enzymes can be modulated by many environmental toxins or drugs, which can affect
the toxicity and efficacy of co-medicated drugs and cause drug–drug interactions [119–122]. Recently,
Tompkins et al. investigated the effect of nineteen excipients on regulation of CYP3A4 expression in
human liver and colon cells [118]. CYP3A4 is a highly inducible isoenzyme and is mainly regulated
by a xenobiotic receptor named Pregnane X receptor (PXR), at the transcription level [123,124]. This
study also included a PXR activation assay to predict the effect of excipients on CYP3A4 expression.
As a result, all the excipients failed to activate the CYP2B6 promoter used for PXR activation assay.
Instead, few excipients (HPMC, pregelatinized starch and polysorbate-80) showed a decrease in the
multi-drug resistance gene (MDR1) and CYP3A4 expression (Table 7). These results suggest that
excipients stimulate their effect via an alternate route.
Table 7. Effect of excipients on PXR activation, CYP3A4 and MDR1. change.
Excipients Fa2N4 HPH LS174T
mRNA Protein mRNA Protein CYP3A4 MDR1
HPMC ↑ ↓ = x ↓ ↓a
Pregelatinized
starch = = ↓ x ↓ ↓
Croscarmellose
sodium ↑ = ↑ x ↓a ↓a
Crospovidone ↑a ↓ = x ↓ ↓a
Polysorbate-80 ↓ ↓ ↓ ↓ = =
All the excipients failed to activate PXR but reduced expression of CYP3A4 and MDR1. ↑: increase in expression, ↓:
decrease in expression, =: no change, x: not measured, a: no significant.
Based on a previous study, Takeshita et al. evaluated the effect of plasticizers on PXR-mediated
transcription by the luciferase receptor, PXR-coactivator interaction, PXR knockdown, CYP3A4 activity
assay and PCR analysis of CYP3A4 enzyme expression [125]. Tompkins et al. (2010) used only two
plasticizers which showed no effect on PXR or CYP3A4 induction. However, this study was focused
on eight pharmaceutical plasticizers: acetyl tributyl citrate (ATBC), acetyl triethyl citrate, tributyl
citrate, triethyl citrate, diethyl phthalate, dibutyl phthalate, triacetin and dibutyl sebacate. As a
result, ATBC, dibutyl phthalate and acetyl triethyl citrate activated PXR. ATBC being the most potent
transcription inducer showed dose-dependent activation. However, ATBC induced only intestinal
CYP3A4 expression and not hepatic expression. This could be due to the PXR splice variants that vary
in their gene targets, expression patterns, ligands, biological functions, subcellular localization and
protein interactions [125]
6. Conclusions
Pharmaceutical excipients play an important role in pharmaceutical products and are often
presumed to be pharmacologically inert. However, there is growing evidence that they can change the
pharmacokinetics of APIs through various mechanisms, such as P-gp inhibition and CYP450 inhibition.
In this review, we present recent research concerning the effects of common pharmaceutical excipients
on pre-systemic metabolism by phase I metabolic enzymes (CYP450). According to our review, more
than 40 commonly-used excipients were revealed to interfere with different isoforms of CYP450 in vitro,
although very few have been assessed in humans. Based on the evidence, the mechanism of action was
mainly found to be direct inhibition of the enzymes. Out of all the various excipients, surfactants were
the most potent inhibitors due to their ability to cause perturbation of the enzyme’s microenvironment.
Despite many similarities in the results from different articles, there appears to be a need for a robust
approach to integrate the in vitro data that can predict pharmacokinetic changes in humans. Further
research investigations are warranted to shed light on this issue.
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API Active Pharmaceutical Ingredient
AUC Area Under the Curve
CMC Critical Micellar Concentration
CTAB Cetyltrimethylammonium Bromide
CYP450 Cytochrome P450
DHB Dihydroxybergamottin
DMSO Dimethyl Sulfoxide
FA Fatty Acids
GIT Gastrointestinal Tract
HPC Hydroxypropyl Cellulose
HPMC Hydroxypropyl Methylcellulose
IC50 Inhibitory Concentration
Ki Inhibitory Constant
Clint Intrinsic Clearance
mRNA Messenger RNA
MDZ Midazolam
Mw Molecular weight
MDR1 Multi-drug Resistance Gene
mPEGx-PCLx Methoxy Poly(ethylene glycol)-poly(ε-caprolactone) (mPEGx-PCLx)
ATBC Acetyl Tributyl Citrate
F68 Pluronic F68
PEG Polyethylene Glycol
PVA Polyvinyl Acetate
PVP Polyvinyl Pyrrolidone
PXR Pregnane X receptor
SDS Sodium Dodecyl Sulfate
SEDSS Self-emulsifying Drug Delivery System
SMEDDS Self-micro Emulsifying Drug Delivery System
NaCMC Sodium Carboxymethyl Cellulose
NI No Inhibition
TPGS D -α-Tocopherol Polyethylene Glycol 1000 Succinate
TX-100 Triton X-100
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